Arcturus Therapeutics Holdings Stock Annual Yield
ARCT Stock | USD 18.64 0.30 1.64% |
Arcturus Therapeutics Holdings fundamentals help investors to digest information that contributes to Arcturus Therapeutics' financial success or failures. It also enables traders to predict the movement of Arcturus Stock. The fundamental analysis module provides a way to measure Arcturus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcturus Therapeutics stock.
Arcturus | Annual Yield |
Arcturus Therapeutics Holdings Company Annual Yield Analysis
Arcturus Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Arcturus Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcturus Therapeutics is extremely important. It helps to project a fair market value of Arcturus Stock properly, considering its historical fundamentals such as Annual Yield. Since Arcturus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcturus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcturus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Arcturus Therapeutics Holdings has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
All Next | Launch Module |
Arcturus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcturus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcturus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcturus Fundamentals
Return On Equity | -0.23 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (0.39) % | ||||
Operating Margin | (0.26) % | ||||
Current Valuation | 289.03 M | ||||
Shares Outstanding | 27.09 M | ||||
Shares Owned By Insiders | 8.45 % | ||||
Shares Owned By Institutions | 90.17 % | ||||
Number Of Shares Shorted | 4.48 M | ||||
Price To Earning | 119.50 X | ||||
Price To Book | 1.90 X | ||||
Price To Sales | 3.15 X | ||||
Revenue | 157.75 M | ||||
Gross Profit | 62.95 M | ||||
EBITDA | (24.17 M) | ||||
Net Income | (29.73 M) | ||||
Cash And Equivalents | 283.49 M | ||||
Cash Per Share | 10.67 X | ||||
Total Debt | 30.22 M | ||||
Debt To Equity | 0.58 % | ||||
Current Ratio | 3.14 X | ||||
Book Value Per Share | 9.67 X | ||||
Cash Flow From Operations | (18.1 M) | ||||
Short Ratio | 11.75 X | ||||
Earnings Per Share | (2.33) X | ||||
Target Price | 79.47 | ||||
Number Of Employees | 180 | ||||
Beta | 2.64 | ||||
Market Capitalization | 504.91 M | ||||
Total Asset | 429.4 M | ||||
Retained Earnings | (367.87 M) | ||||
Working Capital | 304.6 M | ||||
Current Asset | 54.55 M | ||||
Current Liabilities | 3.52 M | ||||
Net Asset | 429.4 M |
About Arcturus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcturus Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcturus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcturus Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.